Mosaic ImmunoEngineering Inc
For the period ended Dec 31, 2023. Filed Apr 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 15, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. Executive Compensation
| ITEM 11. | EXECUTIVE COMPENSATION |
|---|
The following table summarizes the compensation of the named executive officers for the years ended December 31, 2023 and 2022.
| Name and Principal Position · Year · Salary ($) · Bonus ($) · Stock Awards ($) · All Other Compensation ($) · Total Compensation ($) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Steven King, President and Chief | 2023 | $250,000 | (1) | $– | $– | $17,844 | (2) | $267,844 |
| Executive Officer (“CEO”) | 2022 | $250,000 | (1) | $– | $– | $16,322 | (2) | $266,322 |
| Paul Lytle, EVP, Chief Financial | 2023 | $250,000 | (1) | $– | $– | $45,526 | (2) | $295,526 |
| Officer (“CFO”) | 2022 | $250,000 | (1) | $– | $– | $41,647 | (2) | $291,647 |
| (1) | Of such amount, Mr. King and Mr. Lytle have agreed to defer 85% of their base salary payable in cash until such a time that the Company is able to raise at least $4 million in funding. |
| (2) | Represents the cost of benefits paid on behalf of the named executive officer for health, dental, and vision benefits. |
Outstanding Equity Awards
The following table sets forth certain information regarding unexercised stock options and unvested stock awards held by our named executive officers as of December 31, 2023:
| Option Awards · Stock Awards | ||||||||
|---|---|---|---|---|---|---|---|---|
| Name · Grant Date · Number of Securities Underlying Unexercised Options (#) Exercisable · Number of Securities Underlying Unexercised Options (#) Unexercisable(1) · Option Exercise Price ($) · Option Expiration Date · Number of Shares or Units of Stock That Have Not Vested (#) · Market Value of Shares or Units of Stock That Have Not Vested ($)(3) | ||||||||
| Steven King | 12/16/2020 | (1) | – | – | – | – | 65,218 | 39,131 |
| 12/16/2020 | (2) | – | – | – | – | 43,479 | 26,087 | |
| Paul Lytle | 12/16/2020 | (1) | – | – | – | – | 42,392 | 25,435 |
| 12/16/2020 | (2) | – | – | – | – | 37,772 | 22,663 | |
| (1) | RSU award will vest 100% on the sooner of (i) August 31, 2026, provided the Company is listed on a national exchange such as the Nasdaq Stock Market prior to August 31, 2026 (ii) upon a merger or acquisition of the Company, provided the holder agrees to accept the underlying shares in writing, or (iii) upon the holders last date of employment, provided the holder agrees to accept the underlying shares in writing. |
| (2) | RSU award will vest 100% on the sooner of (i) August 31, 2024, provided the Company is listed on a national exchange such as the Nasdaq Stock Market prior to August 31, 2024 (ii) upon a merger or acquisition of the Company, provided the holder agrees to accept the underlying shares in writing, or (iii) upon the holders last date of employment, provided the holder agrees to accept the underlying shares in writing. |
| (3) | Market value is calculated based on the closing price of our common stock of $0.60 per share on December 31, 2023, times the number of shares subject to the RSU award. Each RSU represents the contingent right to receive, upon vesting, one share of our common stock. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.